Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidyl-dipeptidase A is a membrane-bound, chloride-dependent glycoprotein enzyme that acts as an exopeptidase, catalyzing the release of C-terminal dipeptides from oligopeptides. It is most notable for its role in converting angiotensin I to angiotensin II, a key step in blood pressure regulation. The enzyme does not act on peptide bonds where the penultimate residue (Xaa) is proline or the terminal residue (Yaa) is aspartic acid or glutamic acid. It also inactivates bradykinin. Selective inhibitors targeting peptidyl-dipeptidase A are widely used as antihypertensive agents.
Inhibition of angiotensin I conversion to angiotensin II, thereby reducing vasoconstriction and blood pressure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidyl-dipeptidase A (None).